"AbbVie recognises the need for more Crohn's disease treatment options that can help address both rapid symptom relief and visible reduction of intestinal lining damage," said Thomas Hudson, M.D., senior vice president of research and development and chief scientific officer at AbbVie. "We're pleased that RINVOQ may provide this relief and that it is now available to treat Crohn's disease."